ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

emrusolmin

Also written as “TEV-56286”, “anle138b” and “TEV-56286 Test”.

Its studies are mostly in Multiple System Atrophy · Parkinson Disease, led by 2 companies.

Drug pageEmrusolmin: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Aug 20, 20248 company-led studies, 3 open or runningLicense: MODAG → Teva, Oct 2021Next primary completion: Jan 15, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Teva Pharmaceutical Industriesits history only53 open or runningphase 2since Aug 20, 2024Aug 20, 2024Jan 15, 2027phase 1 · NCT07674940
MODAG30 open or runningphase 1since Dec 16, 2019Dec 16, 2019none ahead

Also a collaborator on its studies: Aptuit and Quotient Sciences.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of MODAG only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2019First study: phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyFirst studyNCT04208152 · 68 enrolled · United Kingdom
  2. Dec 17, 2020Phase 1 study in Parkinson DiseaseNCT04685265 · 70 enrolled · United Kingdom
  3. Oct 26, 2021Teva licensed it from MODAGLicenseWorldwide rights · announced · Teva and MODAG (release)
  4. Jan 25, 2022Named emrusolminINNProposed as its International Nonproprietary Name in WHO's List 126 · before, TEV-56286
  5. Sep 4, 2022Phase 1 study in Parkinson Disease 4, Autosomal Dominant Lewy BodyNCT05532358 · 54 enrolled · United Kingdom

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 MODAG leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05532358Parkinson Disease 4, Autosomal Dominant Lewy Body · United Kingdom1CompletedJan 28, 202354
NCT04685265Parkinson Disease · United Kingdom1CompletedNov 7, 202270
NCT04208152Parkinson Disease 4, Autosomal Dominant Lewy Body · United Kingdom1CompletedAug 4, 202068

How it is read

Names in the registry

  • “TEV-56286”, 4 entries
  • “anle138b”, 2 entries
  • “TEV-56286 Test”, 1 entry
  • “TEV-56286 Reference”, 1 entry
  • “anle138b (TEV-56286)”, 1 entry

Codes read as this program: TEV56286.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.